Company Profile
AN2 Therapeutics Stock Price, News & Analysis
- Ticker:
- ANTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.87 USD (-0.68%)
Close
Last updated: August 11, 2026
147M USD
Market cap
Why the stock is moving
The latest monitored company update is “AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights.” The corresponding closing-price reaction is not yet available.
Company overview
Boron-Based Drug Development
AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology.
Epetraborole in Polycythemia Vera
AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera. The program will evaluate whether the drug can maintain hematocrit control and reduce phlebotomy frequency.
Epetraborole in M. abscessus
Epetraborole is also being studied in an investigator-initiated Phase 2 trial for *Mycobacterium abscessus* lung disease. The study is intended to establish clinical proof of concept and inform a potential pivotal program.
Chagas Disease Program
AN2-502998 is an oral CPSF3 inhibitor for chronic Chagas disease. Its development is supported by translational efficacy work in naturally infected non-human primates.
Oncology Discovery Pipeline
AN2 has declared a boron-containing ENPP1 inhibitor for solid tumors and is also researching PI3Kα and other difficult-to-drug targets in oncology and bone disorders.
Future catalysts
- IND filing for the EBO-PV-201 study of epetraborole in polycythemia vera in the third quarter of 2026.
- Initiation of Phase 2 enrollment in EBO-PV-201 in the fourth quarter of 2026.
- Initiation of a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease in late 2026.
- Initial Part 1 data from EBO-PV-201 during 2027.
- Topline results from the investigator-initiated Phase 2 epetraborole study in *M. abscessus* lung disease in late 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AN2 Therapeutics (ANTX)?
AN2 Therapeutics (ANTX) most recently closed at 5.87 USD, a -0.68% move versus the previous session.
What is the market cap of AN2 Therapeutics (ANTX)?
AN2 Therapeutics currently has a market capitalization of 147M USD on BioPharmSignal.
What does AN2 Therapeutics do?
Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera. The...
On which exchange is ANTX stock listed?
AN2 Therapeutics (ANTX) is associated with NASDAQ, United States, Biopharma.
What is EBO-PV-201?
IND filing for the EBO-PV-201 study of epetraborole in polycythemia vera in the third quarter of 2026.
Which conditions is AN2 Therapeutics targeting with EBO-PV-201?
AN2 Therapeutics is associated with oncology, hematology based on its company overview and current catalyst commentary.
How does AN2 Therapeutics describe recent progress with EBO-PV-201?
IND filing for the EBO-PV-201 study of epetraborole in polycythemia vera in the third quarter of 2026.
What is proof-of-concept?
Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera.